Innovent Biologics, Inc. (SEHK: 1801)
Health Care · Biotechnology · CN
HK$92.65
+0.05% today · -2.6% 1Y
Innovent Biologics, Inc. (SEHK: 1801) operates in the Biotechnology industry within the Health Care sector. The company is valued at $20.55B and employs 8,754 people.
Over the last twelve months the share price has lost 2.6%, trading between 69.55 and 112.70.
Tweenvest scores Innovent Biologics, Inc. across four factors: quality 67/100, value 38/100, growth 100/100. Its strongest factor is growth.
1801 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.55B
- Revenue (TTM)
- $2.31B
- P/E
- 115.33
- EPS
- 0.70
- Dividend yield
- —
- Beta (5Y)
- 0.33
- 52-week high
- HK$112.70
- 52-week low
- HK$69.55
- Avg volume (3M)
- —
- Shares outstanding
- 1.74B
- Employees
- 8,754
- Next earnings
- —
About Innovent Biologics, Inc.
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
- ISIN
- KYG4818G1010
- Founded
- 2011
- Listed since
- Oct 31, 2018
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| United Therapeutics CorporationNasdaqGS: UTHR | $23.55B | $549.16 | +3.07% |
| Incyte CorporationNasdaqGS: INCY | $22.86B | $112.79 | +0.04% |
| Insmed IncorporatedNasdaqGS: INSM | $21.97B | $100.60 | +0.12% |
| Genmab A/SCPSE: GMAB | $21.89B | Dkr2,445.00 | +3.78% |
| PharmaEssentia CorporationTWSE: 6446 | $15.49B | NT$1,195.00 | +2.58% |
| Ascendis Pharma A/SNasdaqGS: ASND | $15.05B | $229.23 | +2.94% |
| Swedish Orphan Biovitrum AB (publ)OM: SOBI | $14.91B | Skr428.40 | +0.14% |
| Exelixis, Inc.NasdaqGS: EXEL | $14.83B | $59.86 | +1.42% |
Figures last refreshed Oct 11, 2026.